drugset / Trial / NCT02761395

Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major

NCT02761395

Unknown 60 enrolled Tanta University
RandomizedParallel-groupSingle-blindTreatment

Summary

1. Evaluate the therapeutic effects, health benefits, and immunological effect of Al-hijamah in children with beta thalassemia major. 2. Evaluate the extent of clinical improvement, reductions in serum iron and ferritin, antioxidant status, in those patients.

Timeline

Start
2015-11
Primary completion
2017-05
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Background Deferasirox Unknown 20 mg/kg Oral
Background Deferasirox Unknown 40 mg/kg Oral